Survival advantage and clinicopathological significance of microRNA-22 in cancers: a meta-analysis

References

• Bray F, Ren JS, Masuyer E, Ferlay J. Global estimates of cancer prevalence for 27 sites in the adult population in 2008. Int J Cancer. 2013;132(5):1133–1145. doi:10.1002/ijc.2771122752881
   PubMed Web of Science ®Google Scholar
• Dai J, Tang K, Xiao W, et al. Prognostic significance of C-reactive protein in urological cancers: a systematic review and meta-analysis. Asian Pac J Cancer Prev. 2014;15(8):3369–3375. doi:10.7314/apjcp.2014.15.8.336924870724
   PubMedGoogle Scholar
• Zeng R, Duan L, Kong Y, et al. Clinicopathological and prognostic role of MMP-9 in esophageal squamous cell carcinoma: a meta-analysis. Chin J Cancer Res. 2013;25(6):637–645. doi:10.3978/j.issn.1000-9604.2013.11.0324385690
   PubMed Web of Science ®Google Scholar
• Carthew RW, Sontheimer EJ. Origins and mechanisms of miRNAs and siRNAs. Cell. 2009;136(4):642–655. doi:10.1016/j.cell.2009.01.03519239886
   PubMed Web of Science ®Google Scholar
• Lee RC, Feinbaum RL, Ambros V, The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell. 1993;75(5):843–854. doi:10.1016/0092-8674(93)90529-y8252621
   PubMed Web of Science ®Google Scholar
• Hu HY, He L, Fominykh K, et al. Evolution of the human-specific microRNA miR-941. Nat Commun. 2012;3:1145. doi:10.1038/ncomms214623093182
   PubMed Web of Science ®Google Scholar
• Zhan S, Merlin C, Boore JL, Reppert SM. The monarch butterfly genome yields insights into long-distance migration. Cell. 2011;147(5):1171–1185. doi:10.1016/j.cell.2011.09.05222118469
   PubMed Web of Science ®Google Scholar
• Fu Y, Yang Y, Zhang H, et al. The genome of the Hi5 germ cell line from Trichoplusia ni, an agricultural pest and novel model for small RNA biology. Elife. 2018;7. doi:10.7554/eLife.42270
   Web of Science ®Google Scholar
• Landgraf P, Rusu M, Sheridan R, et al. A mammalian microRNA expression atlas based on small RNA library sequencing. Cell. 2007;129(7):1401–1414. doi:10.1016/j.cell.2007.04.04017604727
   PubMed Web of Science ®Google Scholar
• Filipowicz W, Bhattacharyya SN, Sonenberg N. Mechanisms of post-transcriptional regulation by microRNAs: are the answers in sight? Nat Rev Genet. 2008;9(2):102–114. doi:10.1038/nrg229018197166
   PubMed Web of Science ®Google Scholar
• Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004;116(2):281–297. doi:10.1016/s0092-8674(04)00045-514744438
   PubMed Web of Science ®Google Scholar
• Zhang B, Pan X, Cobb GP, Anderson TA. Plant microRNA: a small regulatory molecule with big impact. Dev Biol. 2006;289(1):3–16. doi:10.1016/j.ydbio.2005.10.03616325172
   PubMed Web of Science ®Google Scholar
• Guz M, Rivero-Muller A, Okon E, et al. MicroRNAs-role in lung cancer. Dis Markers. 2014;2014:218169. doi:10.1155/2014/59409324744457
   PubMed Web of Science ®Google Scholar
• Ling H, Fabbri M, Calin GA. MicroRNAs and other non-coding RNAs as targets for anticancer drug development. Nat Rev Drug Discov. 2013;12(11):847–865. doi:10.1038/nrd414024172333
   PubMed Web of Science ®Google Scholar
• Bouyssou JM, Manier S, Huynh D, Issa S, Roccaro AM, Ghobrial IM. Regulation of microRNAs in cancer metastasis. Biochim Biophys Acta. 2014;1845(2):255–265. doi:10.1016/j.bbcan.2014.02.00224569228
   PubMed Web of Science ®Google Scholar
• Gurha P, Abreu-Goodger C, Wang T, et al. Targeted deletion of microRNA-22 promotes stress-induced cardiac dilation and contractile dysfunction. Circulation. 2012;125(22):2751–2761. doi:10.1161/CIRCULATIONAHA.111.04435422570371
   PubMed Web of Science ®Google Scholar
• Berenguer J, Herrera A, Vuolo L, et al. MicroRNA 22 regulates cell cycle length in cerebellar granular neuron precursors. Mol Cell Biol. 2013;33(14):2706–2717. doi:10.1128/MCB.00338-1323671190
   PubMed Web of Science ®Google Scholar
• Choong ML, Yang HH, McNiece I. MicroRNA expression profiling during human cord blood-derived CD34 cell erythropoiesis. Exp Hematol. 2007;35(4):551–564. doi:10.1016/j.exphem.2006.12.00217379065
   PubMed Web of Science ®Google Scholar
• Huang ZP, Wang DZ. miR-22 in cardiac remodeling and disease. Trends Cardiovasc Med. 2014;24(7):267–272. doi:10.1016/j.tcm.2014.07.00525218673
   PubMed Web of Science ®Google Scholar
• Song SJ, Pandolfi PP. miR-22 in tumorigenesis. Cell Cycle. 2014;13(1):11–12. doi:10.4161/cc.2702724231768
   PubMed Web of Science ®Google Scholar
• Wan WN, Zhang YQ, Wang XM, et al. Down-regulated miR-22 as predictive biomarkers for prognosis of epithelial ovarian cancer. Diagn Pathol. 2014;9. doi:10.1186/s13000-014-0178-8
   Web of Science ®Google Scholar
• Li J, Liang SH, Yu HL, Zhang J, Ma DA, Lu X. An inhibitory effect of miR-22 on cell migration and invasion in ovarian cancer. Gynecol Oncol. 2010;119(3):543–548. doi:10.1016/j.ygyno.2010.08.03420869762
   PubMed Web of Science ®Google Scholar
• Delfino KR, Rodriguez-Zas SL. Transcription factor-microRNA-target gene networks associated with ovarian cancer survival and recurrence. PLoS One. 2013;8(3):e58608. doi:10.1371/journal.pone.005860823554906
   PubMed Web of Science ®Google Scholar
• Chen M, Hu W, Xiong CL, et al. miR-22 targets YWHAZ to inhibit metastasis of hepatocellular carcinoma and its down-regulation predicts a poor survival. Oncotarget. 2016;7(49):80751–80764. doi:10.18632/oncotarget.1303727811373
   PubMedGoogle Scholar
• Zhou L, He JT, Zhang YD. MicroRNA-22 expression in hepatocellular carcinoma and its correlation with ezrin protein. J Int Med Res. 2013;41(4):1009–1016. doi:10.1177/030006051348443623766411
   PubMed Web of Science ®Google Scholar
• Chen B, Tang H, Liu X, et al. miR-22 as a prognostic factor targets glucose transporter protein type 1 in breast cancer. Cancer Lett. 2015;356(2Pt B):410–417. doi:10.1016/j.canlet.2014.09.02825304371
   PubMedGoogle Scholar
• Patel JB, Appaiah HN, Burnett RM, et al. Control of EVI-1 oncogene expression in metastatic breast cancer cells through microRNA miR-22. Oncogene. 2011;30(11):1290–1301. doi:10.1038/onc.2010.51021057539
   PubMed Web of Science ®Google Scholar
• Yoshimoto N, Toyama T, Takahashi S, et al. Distinct expressions of microRNAs that directly target estrogen receptor alpha in human breast cancer. Breast Cancer Res Tr. 2011;130(1):331–339. doi:10.1007/s10549-011-1672-2
   PubMed Web of Science ®Google Scholar
• Slattery ML, Herrick JS, Mullany LE, et al. An evaluation and replication of miRNAs with disease stage and colorectal cancer-specific mortality. Int J Cancer. 2015;137(2):428–438. doi:10.1002/ijc.2938425484364
   PubMed Web of Science ®Google Scholar
• Song SJ, Ito K, Ala U, et al. The oncogenic microRNA miR-22 targets the TET2 tumor suppressor to promote hematopoietic stem cell self-renewal and transformation. Cell Stem Cell. 2013;13(1):87–101. doi:10.1016/j.stem.2013.06.00323827711
   PubMed Web of Science ®Google Scholar
• Zuo QF, Cao LY, Yu T, et al. MicroRNA-22 inhibits tumor growth and metastasis in gastric cancer by directly targeting MMP14 and Snail. Cell Death Dis. 2015;6:e2000. doi:10.1038/cddis.2015.297
   Web of Science ®Google Scholar
• Liu N, Cui RX, Sun Y, et al. A four-miRNA signature identified from genome-wide serum miRNA profiling predicts survival in patients with nasopharyngeal carcinoma. Int J Cancer. 2014;134(6):1359–1368. doi:10.1002/ijc.2846823999999
   PubMed Web of Science ®Google Scholar
• Moher D. Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement (vol 8, pg 336, 2010). Int J Surg. 2010;8(8):658. doi:10.1016/j.ijsu.2010.07.299
   Web of Science ®Google Scholar
• Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med. 1998;17(24):2815–2834.9921604
   PubMed Web of Science ®Google Scholar
• Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials. 2007;8. doi:10.1186/1745-6215-8-16
   PubMed Web of Science ®Google Scholar
• Stroup DF, Berlin JA, Morton SC, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. Jama. 2000;283(15):2008–2012. doi:10.1001/jama.283.15.200810789670
   PubMed Web of Science ®Google Scholar
• Hong L, Han Y, Yang J, et al. Prognostic value of epidermal growth factor receptor in patients with gastric cancer: a meta-analysis. Gene. 2013;529(1):69–72. doi:10.1016/j.gene.2013.07.10623954221
   PubMed Web of Science ®Google Scholar
• Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21(11):1539–1558. doi:10.1002/sim.118612111919
   PubMed Web of Science ®Google Scholar
• Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959;22(4):719–748.13655060
   PubMed Web of Science ®Google Scholar
• DerSimonian R, Laird N. Meta-analysis in clinical trials revisited. Contemp Clin Trials. 2015;45(Pt A):139–145. doi:10.1016/j.cct.2015.09.00226343745
   PubMed Web of Science ®Google Scholar
• Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315(7109):629–634. doi:10.1136/bmj.315.7109.6299310563
   PubMed Web of Science ®Google Scholar
• Li X, Lu Y, Chen YX, Lu WG, Xie X. MicroRNA profile of paclitaxel-resistant serous ovarian carcinoma based on formalin-fixed paraffin-embedded samples. BMC Cancer. 2013;13. doi:10.1186/1471-2407-13-216
   Web of Science ®Google Scholar
• Zhang J, Yang Y, Yang T, et al. microRNA-22, downregulated in hepatocellular carcinoma and correlated with prognosis, suppresses cell proliferation and tumourigenicity. British Journal of Cancer. 2010;103(8):1215–1220.doi: 10.1038/sj.bjc.660589520842113
   PubMed Web of Science ®Google Scholar
• Zhang GJ, Xia SS, Tian HP, Liu ZL, Zhou T. Clinical significance of miR-22 expression in patients with colorectal cancer. Medical Oncology. 2012;29(5):3108–3112.doi: 10.1007/s12032-012-0233-922492279
   PubMed Web of Science ®Google Scholar
• Xia SS, Zhang GJ, Liu ZL, et al. MicroRNA-22 suppresses the growth, migration and invasion of colorectal cancer cells through a Sp1 negative feedback loop. Oncotarget. 2017;8(22):36266–36278.doi: 10.18632/oncotarget.1674228422727
   PubMedGoogle Scholar
• Tang Y, Liu X, Su B, et al. microRNA-22 acts as a metastasis suppressor by targeting metadherin in gastric cancer. Mol Med Rep. 2015;11(1):454–460.doi: 10.3892/mmr.2014.268225323629
   PubMed Web of Science ®Google Scholar
• Wang W, Li F, Zhang Y, Tu Y, Yang Q, Gao X. Reduced expression of miR-22 in gastric cancer is related to clinicopathologic characteristics or patient prognosis. Diagn Pathol. 2013;8:102. doi:10.1186/1746-1596-8-10223786758
   PubMed Web of Science ®Google Scholar
• Fan W, Huang J, Xiao H, Liang Z. MicroRNA-22 is downregulated in clear cell renal cell carcinoma, and inhibits cell growth, migration and invasion by targeting PTEN. Mol Med Rep. 2016;13(6):4800–4806.doi: 10.3892/mmr.2016.510127082730
   PubMed Web of Science ®Google Scholar
• Zhang S, Zhang D, Yi C, Wang Y, Wang H, Wang J. MicroRNA-22 functions as a tumor suppressor by targeting SIRT1 in renal cell carcinoma. Oncol Rep. 2016;35(1):559–567.doi: 10.3892/or.2015.433326499759
   PubMed Web of Science ®Google Scholar
• Wang G, Shen N, Cheng L, Lin J, Li K. Downregulation of miR-22 acts as an unfavorable prognostic biomarker in osteosarcoma. Tumour Biol. 2015;36(10):7891–7895. doi:10.1007/s13277-015-3379-125953260
   PubMedGoogle Scholar
• Song SJ, Poliseno L, Song MS, Ala U, Webster K, Ng C, Beringer G, Brikbak NJ, Yuan X, Cantley LC, Richardson AL, Pandolfi PP. MicroRNA-Antagonism Regulates Breast Cancer Stemness and Metastasis via TET-Family-Dependent Chromatin Remodeling. Cell 2013;154:311–24.doi:10.1016/j.cell.2013.06.02623830207
   PubMed Web of Science ®Google Scholar
• Wang XC, Zhang ZB, Wang YY, et al. Increased miRNA-22 expression sensitizes esophageal squamous cell carcinoma to irradiation. J Radiat Res. 2013;54(3):401–408.doi:10.1093/jrr/rrs11323188185
   PubMed Web of Science ®Google Scholar
• Li R, Wang J, Yang S. miR-22 inhibited glioma cells proliferation by targeting MTDH. China Oncol. 2014;24(6):401–406.
   Google Scholar
• Lionetti M, Musto P, Di Martino MT, et al. Biological and clinical relevance of miRNA expression signatures in primary plasma cell leukemia. Clin Cancer Res. 2013;19(12):3130–3142. doi:10.1158/1078-0432.CCR-12-204323613318
   PubMed Web of Science ®Google Scholar
• Du L, Jiang X, Duan W, et al. Cell-free microRNA expression signatures in urine serve as novel noninvasive biomarkers for diagnosis and recurrence prediction of bladder cancer. Oncotarget. 2017. doi:10.18632/oncotarget.16586
   Google Scholar
• Zou Q, Tang Q, Pan Y, et al. MicroRNA-22 inhibits cell growth and metastasis in breast cancer via targeting of SIRT1. Exp Ther Med. 2017;14(2):1009–1016. doi:10.3892/etm.2017.459028781618
   PubMed Web of Science ®Google Scholar
• Zhang BH, Pan XP, Cobb GP, Anderson TA. microRNAs as oncogenes and tumor suppressors. Dev Biol. 2007;302(1):1–12. doi:10.1016/j.ydbio.2006.08.02816989803
   PubMed Web of Science ®Google Scholar
• Kent OA, Mendell JT. A small piece in the cancer puzzle: microRNAs as tumor suppressors and oncogenes. Oncogene. 2006;25(46):6188–6196. doi:10.1038/sj.onc.120991317028598
   PubMed Web of Science ®Google Scholar
• Kim DJ, Linnstaedt S, Palma J, et al. Plasma components affect accuracy of circulating cancer-related microRNA quantitation. J Mol Diagn. 2012;14(1):71–80. doi:10.1016/j.jmoldx.2011.09.00222154918
   PubMed Web of Science ®Google Scholar
• Miska EA. How microRNAs control cell division, differentiation and death. Curr Opin Genet Dev. 2005;15(5):563–568. doi:10.1016/j.gde.2005.08.00516099643
   PubMed Web of Science ®Google Scholar
• Zheng H, Li P, Kwok JG, et al. Alcohol and hepatitis virus-dysregulated lncRNAs as potential biomarkers for hepatocellular carcinoma. Oncotarget. 2018;9(1):224–235. doi:10.18632/oncotarget.2292129416609
   PubMedGoogle Scholar
• Shenouda SK, Alahari SK. MicroRNA function in cancer: oncogene or a tumor suppressor? Cancer Metastasis Rev. 2009;28(3–4):369–378. doi:10.1007/s10555-009-9188-520012925
   PubMed Web of Science ®Google Scholar